Bartolo S, Vambergue A, Deruelle P
Clinique d'obstétrique, pôle femme-mère-nouveau-né, CHU de Lille, 59037 Lille cedex, France.
Pôle d'endocrinologie, CHU de Lille, 59037 Lille cedex, France; UMR 8199, université Lille 2, EGID, 59037 Lille cedex, France.
J Gynecol Obstet Biol Reprod (Paris). 2016 Feb;45(2):105-11. doi: 10.1016/j.jgyn.2015.12.004. Epub 2016 Jan 15.
For many years, there is a debate on gestational diabetes screening, including what screening test and thresholds to use. The purpose of this literature review is to determine whether gestational diabetes screening in France meets the 10 definition criteria of the WHO. The DG is a public health problem, with a natural history partially known and detectable at an early stage. Currently, there is no data showing that there is a benefit to treat patient screens by the new criteria. The one-step approach-screening test can only detect fetal complications and not maternal complications. It seems to be acceptable for the population of pregnant women. The diagnostic test and treatment also seem to be acceptable to us. To this day, its reproducibility is uncertain. Screening leads to an increase in obstetric interventions. Several studies found that screening for gestational diabetes is cost-effective but in a different context of care than in France.
多年来，关于妊娠期糖尿病筛查存在诸多争论，包括采用何种筛查测试及阈值。本综述的目的是确定法国的妊娠期糖尿病筛查是否符合世界卫生组织的10项定义标准。妊娠期糖尿病是一个公共卫生问题，其自然病史部分已知且可在早期检测到。目前，尚无数据表明按照新标准对筛查出的患者进行治疗有何益处。一步法筛查测试仅能检测出胎儿并发症，而非母体并发症。这对孕妇群体而言似乎是可以接受的。诊断测试和治疗对我们来说似乎也可以接受。时至今日，其可重复性尚不确定。筛查会导致产科干预增加。多项研究发现，妊娠期糖尿病筛查具有成本效益，但所处的护理背景与法国不同。
